Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type ( Recombinant FSH, Urinary FSH), By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others), By Region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 1.20 billion

CAGR (2023-2028)

5.76%

Fastest Growing Segment

Urinary FSH

Largest Market

North America


Market Overview

Global Follicle Stimulating Hormone Market has valued at USD 1.20 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.76% through 2028. The global Follicle Stimulating Hormone (FSH) market has been a critical player in the healthcare industry for decades. FSH is a vital hormone that plays a significant role in human reproduction, making it a fundamental component of fertility treatments and hormone replacement therapy. As the world's population continues to age, infertility rates rise, and awareness about hormone-related disorders increases, the FSH market has witnessed significant growth and innovation. Follicle Stimulating Hormone, produced by the anterior pituitary gland, is a key regulator of the reproductive system in both men and women. In females, FSH stimulates the growth of ovarian follicles and triggers ovulation. In males, it stimulates the testes to produce sperm. Dysregulation of FSH levels can lead to various reproductive health issues, including infertility, irregular menstrual cycles, and hormone imbalances.

The global population is aging, with an increasing number of women seeking fertility treatments as they delay parenthood. This demographic trend has led to a surge in demand for FSH-based therapies to enhance fertility. Increasing awareness about fertility issues and hormone-related disorders, driven by advancements in healthcare information dissemination, has encouraged more people to seek medical assistance, thereby driving FSH market growth. Innovations in the field of biotechnology and pharmaceuticals have led to the development of more effective FSH products and therapies, offering improved results and fewer side effects. Governments in many countries have taken steps to support assisted reproductive technologies and hormone replacement therapies. This includes subsidizing treatments, reducing regulatory barriers, and funding research in the field.

Ky Market Drivers

Increasing Prevalence of Infertility is Driving the Global Follicle Stimulating Hormone Market

Infertility has become a growing concern worldwide, affecting millions of couples who dream of starting a family. In recent years, the prevalence of infertility has been on the rise, contributing to the expansion of the global Follicle Stimulating Hormone (FSH) market. FSH, a crucial hormone for reproductive health, has gained prominence as a key player in fertility treatments. Infertility is a medical condition defined by the inability to conceive after a year of regular, unprotected sexual intercourse. It can result from various factors, including hormonal imbalances, age-related declines in fertility, structural issues, and lifestyle factors.

Changing societal trends, including delayed marriages and career-focused lifestyles, have led many couples to postpone starting a family until later in life. Unfortunately, female fertility declines with age, making conception more challenging. Environmental toxins, pollutants, and the exposure to endocrine-disrupting chemicals have been linked to fertility issues. These factors can disrupt hormonal balance, including FSH levels, crucial for healthy reproductive function. The modern lifestyle, characterized by high stress levels, sedentary habits, and poor dietary choices, can negatively impact fertility. Stress hormones can interfere with reproductive hormones, including FSH.

Follicle Stimulating Hormone, produced by the pituitary gland, plays a central role in the reproductive system. It is responsible for stimulating the ovaries in women and the testes in men, encouraging the growth and maturation of follicles in the ovaries and the production of sperm in men. FSH levels are a critical indicator of the health and function of the reproductive system. The escalating prevalence of infertility has given rise to increased demand for fertility treatments. FSH has emerged as a key component of these treatments, fueling the growth of the global FSH market.

Techniques such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) have become more prevalent. These procedures often require FSH to stimulate the development of multiple follicles, increasing the chances of successful fertilization. As more couples decide to have children later in life, the demand for fertility treatments, including FSH-based therapies, has surged. Greater awareness about fertility issues and available treatments has led more couples to seek help from fertility specialists, leading to increased FSH usage. Many governments and healthcare regulatory bodies are now recognizing infertility as a medical condition and providing support for fertility treatments, including FSH-based therapies.

Growing Aging Population is Driving the Global Follicle Stimulating Hormone Market

The global population is experiencing a significant demographic shift, characterized by a rapidly growing aging population. As people age, their bodies undergo various changes, including hormonal imbalances. One such hormone that plays a crucial role in the aging process is Follicle Stimulating Hormone (FSH). FSH is responsible for regulating the reproductive system, but it also has implications for overall health.

As individuals age, their bodies undergo various changes, including hormonal shifts. In women, the most noticeable change is menopause, which occurs when the ovaries stop producing eggs and estrogen levels decline. FSH levels rise significantly during menopause, indicating the body's attempt to stimulate the ovaries to produce eggs, even though the ovaries have become less responsive. In men, FSH levels also tend to increase with age. This can be attributed to a decrease in testosterone production, as the body attempts to compensate for the declining hormone levels by increasing FSH production. Elevated FSH levels in men are associated with reduced sperm production and fertility.

With the onset of menopause in women, there is a growing demand for hormone replacement therapy (HRT) to alleviate menopausal symptoms. FSH levels play a crucial role in determining the need for HRT, and healthcare providers often measure FSH levels to assess hormonal imbalances in menopausal women. As couples delay parenthood, infertility issues become more common due to age-related declines in fertility. Elevated FSH levels can indicate reduced ovarian reserve in women, prompting the need for fertility treatments such as in vitro fertilization (IVF) or egg freezing. The FSH market benefits from increased demand for these treatments. FSH levels are also used as diagnostic tools for various medical conditions. Elevated FSH levels can indicate conditions such as polycystic ovary syndrome (PCOS) in women or testicular dysfunction in men. The aging population's increased susceptibility to these conditions drives the demand for FSH testing. The aging population's growing health concerns have spurred research and development efforts in the field of hormonal therapies. Pharmaceutical companies are investing in the development of novel therapies and medications targeting FSH-related disorders.

 

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles

One of the foremost challenges confronting the FSH market is the complex regulatory environment. Different countries have varying regulations and approval processes for fertility treatments and hormone therapies. This creates a barrier for companies looking to expand their presence in multiple regions. Navigating these regulatory hurdles demands substantial investments in time and resources, and it often leads to delays in product launches and market entry.

Pricing Pressures

Price is a critical factor in the FSH market, and the pressure to keep prices competitive is relentless. Fertility treatments are often not covered by insurance, placing a significant financial burden on patients. Additionally, the availability of generic versions of FSH drugs can drive down prices, affecting the profitability of pharmaceutical companies. Balancing the need for affordable treatments with the desire for profitability is a constant challenge for market players.

Technological Advancements

While technological advancements have revolutionized the field of assisted reproductive technology (ART), they have also introduced challenges for FSH manufacturers. Continuous innovation leads to the development of more advanced treatment options and the need to update existing products. Keeping up with these technological changes and ensuring that FSH products remain effective and competitive is a significant challenge for companies in the market.

Competition and Market Saturation

The global FSH market is highly competitive, with several established players and new entrants vying for market share. This intense competition can lead to price wars, reducing profit margins and limiting growth opportunities. Market saturation is another concern, as a significant portion of the target patient population may have already undergone fertility treatments, leaving fewer new patients to target.

Ethical and Social Concerns

The ethical and social aspects of fertility treatments, including the use of FSH, are subjects of ongoing debate. Issues related to the availability and affordability of treatments, the moral implications of assisted reproduction, and concerns about overpopulation and environmental impact can affect the public perception of FSH and fertility treatments in general. Companies in the FSH market must address these concerns and engage in transparent communication with the public to maintain a positive image.

Supply Chain Disruptions

The COVID-19 pandemic highlighted the vulnerability of global supply chains, and the FSH market was not immune to disruptions. Interruptions in the supply chain can lead to shortages of FSH products, impacting patient access to critical treatments. Manufacturers must invest in resilient supply chain strategies to mitigate these risks.

Key Market Trends

Technological Advancements

The field of medicine and healthcare is continuously evolving, with technological advancements playing a pivotal role in shaping the future of diagnostics and treatments. One such area experiencing significant growth is the global Follicle Stimulating Hormone (FSH) market. FSH is a critical hormone responsible for regulating the reproductive system in both men and women. The market for FSH has been witnessing remarkable growth, largely driven by advancements in technology and a growing demand for fertility treatments and diagnostic tools.

One of the key technological advancements in the FSH market is the development of highly sensitive assays for FSH measurement. Traditional FSH assays were relatively less precise and had limitations in detecting low levels of the hormone. However, modern immunoassays and automated platforms have greatly improved the accuracy and sensitivity of FSH testing. This has made it easier for healthcare professionals to diagnose and monitor reproductive disorders with precision. Advances in microfluidics and biosensor technologies have led to the development of user-friendly home fertility testing kits. These kits allow individuals to monitor their FSH levels at home, providing valuable insights into their reproductive health. Such technology empowers individuals to take control of their fertility and seek medical intervention when necessary.

Point-of-Care (POC) Testing devices have revolutionized healthcare by enabling rapid and on-site diagnostics. In the FSH market, POC devices have made it possible for healthcare providers to obtain immediate FSH test results, reducing patient wait times and facilitating faster treatment decisions. This is particularly beneficial for fertility clinics and reproductive health centers.

IVF has been a game-changer in the field of assisted reproduction, and ongoing technological advancements continue to improve success rates. Innovations such as time-lapse imaging, genetic screening, and embryo selection algorithms have made IVF more effective and accessible to a broader range of couples struggling with infertility. Advances in cryopreservation methods have extended the viability of eggs and embryos. This has significant implications for women who wish to postpone pregnancy or preserve their fertility before undergoing treatments that may affect reproductive function, such as chemotherapy. The integration of genetics and genomics into fertility treatments has led to the concept of personalized medicine in reproductive healthcare. Genetic testing can identify potential fertility issues and help tailor treatments to individual needs, increasing the chances of a successful pregnancy.

The global FSH market is witnessing robust growth, driven by the convergence of technology and healthcare. The increasing prevalence of reproductive disorders, coupled with a growing awareness of fertility issues, has fueled the demand for FSH testing and fertility treatments. Technological advancements have not only improved the accuracy and accessibility of FSH testing but have also expanded the range of treatment options available to patients. Looking ahead, the FSH market is poised for further expansion. As artificial intelligence, machine learning, and precision medicine continue to advance, the field of reproductive healthcare will benefit from more personalized and effective treatments. Additionally, the integration of telemedicine and telehealth services will enhance access to fertility care, especially in underserved regions.

Type Insights

The Recombinant FSH segment is projected to experience rapid growth during the forecast period. The advent of recombinant DNA technology revolutionized the production of FSH. Recombinant FSH is synthesized using genetically engineered bacteria or yeast, eliminating the need for human donors and providing a more consistent and purer product. These advancements have contributed to the growing popularity of recombinant FSH in the global market. Recombinant FSH offers a higher degree of purity and consistency compared to urine-derived FSH. This ensures that patients receive a reliable and effective treatment, reducing the chances of adverse reactions. The use of recombinant technology eliminates the need to collect urine from postmenopausal women, addressing ethical concerns associated with traditional FSH production methods. Recombinant FSH products have received regulatory approvals from agencies such as the FDA and the European Medicines Agency (EMA), bolstering their credibility and increasing physician and patient trust.

Application Insights

The Infertility Treatment segment is projected to experience rapid growth during the forecast period. Infertility is a prevalent global issue affecting millions of couples worldwide. The inability to conceive naturally can be emotionally and physically taxing, leading many individuals and couples to seek infertility treatments. Among the various approaches available, the use of Follicle Stimulating Hormone (FSH) stands out as a cornerstone in addressing infertility. While FSH is traditionally associated with female fertility, recent research has explored its potential applications in male infertility as well. Some innovative treatments are using FSH to stimulate sperm production in men with hormonal imbalances or certain genetic conditions. This represents a groundbreaking approach to addressing male infertility and expanding the scope of FSH-based treatments.

Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global Follicle Stimulating Hormone market in 2022, holding the largest market share in terms of value. North America boasts a robust healthcare infrastructure with access to cutting-edge medical technologies, state-of-the-art fertility clinics, and research institutions. This facilitates the production, distribution, and administration of FSH treatments efficiently. The United States and Canada have witnessed a steady increase in infertility rates due to various factors, including delayed childbearing, lifestyle changes, and environmental factors. This has driven the demand for fertility treatments, including FSH-based therapies. Increased awareness about fertility treatments and reproductive health options has prompted more individuals and couples to seek assistance in achieving their reproductive goals. This has led to higher FSH usage. North America has a well-established regulatory framework that ensures the safety and efficacy of pharmaceutical products. This boosts confidence in FSH treatments among healthcare professionals and patients. Collaboration between pharmaceutical companies, healthcare providers, and fertility clinics has further fueled the growth of the FSH market in North America. These alliances promote research, education, and patient access to FSH treatments.

Recent Developments

  • In June 2023, Celmatix Inc., a prominent biotechnology firm specializing in women's health and dedicated to ovarian biology, has unveiled promising initial findings in its newest drug initiative. This project aims to create the world's inaugural oral FSH receptor (FSHR) agonist medication, presenting a groundbreaking potential to transform the landscape of fertility treatments.
  • In March 2023, Ferring has revealed the abstract for the inaugural multinational, real-world study of Rekovelle (follitropin delta) during the Pacific Society for Reproductive Medicine's congress.

Key Market Players

  • Merck Serono
  • Creative BioMart inc.
  • Midas Pharma GmbH
  • GenPharm
  • Trumac Healthcare pvt ltd
  • LIVZON PHARMACEUTICAL GROUP INC
  • Shanghai Techwell Biopharmaceutical Co., Ltd.
  • Merck Sharp & Dohme Corp
  • Lee Biosolutions,Inc
  • BIOGENIX INC.PVT.LTD.

By Type

By Application

By Region
  • Recombinant FSH
  • Urinary FSH
  • Infertility Treatment
  • Assisted Reproductive Application (ART)
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Follicle Stimulating Hormone Market, By Type:

o   Recombinant FSH

o   Urinary FSH

  • Follicle Stimulating Hormone Market, By Application:

o   Infertility Treatment

o   Assisted Reproductive Application (ART)

o   Others

  • Follicle Stimulating Hormone Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Follicle Stimulating Hormone Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]   

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Applications

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Impact of COVID-19 on Global Follicle Stimulating Hormone Market

5.    Voice of Customer

6.    Global Follicle Stimulating Hormone Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value                      

6.2.  Market Share & Forecast

6.2.1.     By Type (Recombinant FSH, Urinary FSH)

6.2.2.     By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)

6.2.3.     By Region

6.2.4.     By Company (2022)

6.3.  Market Map

7.    Asia Pacific Follicle Stimulating Hormone Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.2.     By Application

7.2.3.     By Country

7.3.  Asia Pacific: Country Analysis

7.3.1.     China Follicle Stimulating Hormone Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.2.             By Application

7.3.2.     India Follicle Stimulating Hormone Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.2.             By Application

7.3.3.     Australia Follicle Stimulating Hormone Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.2.             By Application

7.3.4.     Japan Follicle Stimulating Hormone Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Type

7.3.4.2.2.             By Application

7.3.5.     South Korea Follicle Stimulating Hormone Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Type

7.3.5.2.2.             By Application

8.    Europe Follicle Stimulating Hormone Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.2.     By Application

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Follicle Stimulating Hormone Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.2.             By Application

8.3.2.     Germany Follicle Stimulating Hormone Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.2.             By Application

8.3.3.     Spain Follicle Stimulating Hormone Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.2.             By Application

8.3.4.     Italy Follicle Stimulating Hormone Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type

8.3.4.2.2.             By Application

8.3.5.     United Kingdom Follicle Stimulating Hormone Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type

8.3.5.2.2.             By Application

9.    North America Follicle Stimulating Hormone Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Application

9.2.3.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Follicle Stimulating Hormone Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Application

9.3.2.     Mexico Follicle Stimulating Hormone Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Application

9.3.3.     Canada Follicle Stimulating Hormone Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Application

10.  South America Follicle Stimulating Hormone Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.2.  By Application

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Follicle Stimulating Hormone Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By Application

10.3.2.  Argentina Follicle Stimulating Hormone Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By Application

10.3.3.  Colombia Follicle Stimulating Hormone Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By Application

11.  Middle East and Africa Follicle Stimulating Hormone Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type

11.2.2.  By Application

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Follicle Stimulating Hormone Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type

11.3.1.2.2.           By Application

11.3.2.  Saudi Arabia Follicle Stimulating Hormone Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type

11.3.2.2.2.           By Application

11.3.3.  UAE Follicle Stimulating Hormone Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Type

11.3.3.2.2.           By Application

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Product Launches

13.3.              Mergers & Acquisitions

14.  Global Follicle Stimulating Hormone Market: SWOT Analysis

15.  Porter’s Five Forces Analysis

15.1.              Competition in the Industry

15.2.              Potential of New Entrants

15.3.              Power of Suppliers

15.4.              Power of Customers

15.5.              Threat of Substitute Product

16.  PESTLE Analysis

17.  Competitive Landscape

17.1.              Merck Serono

17.1.1.  Business Overview

17.1.2.  Company Snapshot

17.1.3.  Products & Services

17.1.4.  Financials (In case of listed companies)

17.1.5.  Recent Developments

17.2.              Creative BioMart inc.

17.3.               Midas Pharma GmbH

17.4.              GenPharm

17.5.              Trumac Healthcare pvt ltd

17.6.              LIVZON PHARMACEUTICAL GROUP INC

17.7.              Shanghai Techwell Biopharmaceutical Co., Ltd.

17.8.              Merck Sharp & Dohme Corp

17.9.              Lee Biosolutions,Inc

17.10.            BIOGENIX INC.PVT.LTD.

18.  Strategic Recommendations

19.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Follicle Stimulating Hormone Market was estimated to be USD 1.20 billion in 2022.

down-arrow

The Global Follicle Stimulating Hormone Market was analyzed for the historical period of 2018 to 2021. While the base year was 2022, estimation for the year 2023 was calculated and the market growth was further forecast for 2024 to 2028.

down-arrow

Merck Serono, Creative BioMart inc., Midas Pharma GmbH, GenPharm, Trumac Healthcare pvt ltd, LIVZON PHARMACEUTICAL GROUP INC, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions,Inc, BIOGENIX INC.PVT.LTD. are the top players operating in the Global Follicle Stimulating Hormone Market in 2022.

down-arrow

Increasing Prevalence of Infertility and rising investment in research and development are the major drivers for the Global Follicle Stimulating Hormone Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Follicle Stimulating Hormone Market to Grow with a CAGR of 5.76% through 2028

Nov, 2023

Increasing prevalence of infertility and rising investment in research and development are factors driving the global Follicle Stimulating Hormone market in the forecast period 2024-2028.

Why Choose Us